Sionna Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SION | RNTX | ARCT | CTNM | ATYR | VCRE | |
|---|---|---|---|---|---|---|
| Market cap | 211.76M | 67.71M | 358.41M | 322.22M | 21.07M | 259.96M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.1 | — | -3.4 | -4.5 | -0.5 | — |
| Price/book | 0.8 | 6.6 | 2.1 | 1.3 | 0.4 | — |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −83.28% | −39.85% | −29.14% | +12.15% | −74.53% | −44.62% |
| Today | −4.29% | −1.15% | −8.22% | −35.99% | −12.75% | +2.56% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SION news ›Sionna Therapeutics to reduce workforce by 46%
Following the completion of a comprehensive review of its operations, Sionna’s board of directors has approved a workforce reduction of approxim... Sionna Therapeutics to reduce workforce by 46% Following the completion of a comprehensive…
Stifel Nicolaus Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Sionna Therapeutics, Inc., with a price target of $7.00. According to TipRanks, Matteis is a 5-star analyst with an average return of 15.3% and a…
LifeSci Capital Sticks to Its Hold Rating for Sionna Therapeutics, Inc. (SION)
LifeSci Capital analyst Gaurav Maini maintained a Hold rating on Sionna Therapeutics, Inc. today and set a price target of $6.00. Maini covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Liquidia Technologies, and…
Sionna Therapeutics to advance SION-451 + SION-2222 into AscenSION CF POC trial
Sionna Therapeutics (SION) announced plans to advance SION-451 + SION-2222, its preferred proprietary dual combination, into the AscenSION CF Ph... Sionna Therapeutics to advance SION-451 + SION-2222 into AscenSION CF POC trial Sionna…
Sionna Therapeutics price target raised to $6 from $5 at Wedbush
Wedbush raised the firm’s price target on Sionna Therapeutics (SION) to $6 from $5 and keeps a Neutral rating on the shares. The firm notes the ... Sionna Therapeutics price target raised to $6 from $5 at Wedbush Wedbush raised the firm’s…
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in combination with other…
Analysts’ Opinions Are Mixed on These NA Stocks: HealthStream (HSTM), Inter Parfums (IPAR) and Sionna Therapeutics, Inc. (SION)
Analysts have been eager to weigh in on the NA sector with new ratings on HealthStream (HSTM), Inter Parfums (IPAR) and Sionna Therapeutics, Inc. (SION). Canaccord Genuity analyst Richard Close maintained a Hold rating on HealthStream…
Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Target Price of $42.33 According to Brokerages
Read Our Latest Research Report on SION NASDAQ:SION opened at $4.82 on Thursday. The firm has a market capitalization of $217.91 million, a P/E ratio of -2.21 and a beta of 1.00. Sionna Therapeutics has a 52 week low of $4.01 and a 52 week…
Sionna Advances SION-451/SION-2222 Combo Based on SION-719 Analysis
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Sionna Advances SION-451/SION-2222 Combo Based on SION-719…
Silicosis Claims Poised To Grow Amid Fresh Regulatory Focus - Law360
Silicosis Claims Poised To Grow Amid Fresh Regulatory Focus Law360 Try our Advanced Search for more refined results The Practice of Law Deep News & Analysis Silicosis Claims Poised To Grow Amid Fresh Regulatory Focus Law360 is on it, so…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com7
-
defenseworld.net1
-
firstwordpharma.com1
-
hoodline.com1
-
wboc.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.